• Safety concerns- hypersensitivity reactions, neutropenia, and neufoloxicily (peripheral neuropathy & muscle weakness) 'Domoid t ar ol art Treat Opica:Oncci 16:9 2015 9 EFTA00810560 VERU-111: novel, oral, next generation, tubulin inhibitor targeting a and p subunits of microtubuies Precllnical